NCUK’s CEO, Catherine Bouvier was delighted to be invited to be part of the NET GeCIP review meeting today and gained valuable insights into where we are in terms of analysis of data collected.
The NET GeCIP (Genomics England Clinical Interpretation Partnership) was formed to analyse Neuroendocrine cancer cases which were recruited through the 100,000 genomes project. The project closed to recruitment in 2018, and analysis of the cancer and rare disease cases is ongoing. It is a transformative project which undertook whole genome sequencing in cancer and rare disease at a scale that no other country has every achieved.
The NET GeCIP is a multidisciplinary team of clinicians, researchers, data analysts, trainee doctors and NET patients from across the UK.
So far the GeCIP has identified three inherited DNA mutations in NET cases.and shown that the majority of NET cases have a very low background mutation rate.
Over the next year, with the support of a grant from NCUK, the NET GeCIP are going to focus on fully integrating clinical and treatment information with the DNA sequencing data, analysing the supportive cells which influence tumour formation (tumour microenvironment) and creating new epigenetic data (DNA methylation) which will tell us about environmental impact.
Over recent months we have been working with NCUK to find out what our patients know about the 100,000 genomes project and where they think our research should be directed.
You can read more about the 100,000 Genomes Project here.
#NeuroendocrineCancer #NeuroendocrineCancerUK #NETCancer #NeuroendocrineCancerResearchUK #Genomic #100000GeonomicProject